Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871126 | 0.82 | KDR (0.50) | MAPKAPK2BTKIKBKBKDRCDK4 | |
| SCHEMBL2861737 | 0.81 | MAP2K4 (0.43) | KDRMAPK8MAPK9ADORA2AAURKA | |
| SCHEMBL2857443 | 0.80 | CA12 (0.46) | MAPKAPK2BTKKDRCDK4CCNA2 | |
| SCHEMBL6545000 | 0.78 | TTK (0.40) | MAPKAPK2BTKKDRCDK4CCNA2 | |
| SCHEMBL2864682 | 0.77 | MAPKAPK2 (0.50) | MAPKAPK2BTKIKBKBKDRCDK4 | |
| SCHEMBL2867525 | 0.76 | ALPL (0.50) | MAPKAPK2KDRCDK4CCNA2CCND1 | |
| SCHEMBL2870195 | 0.76 | MAP2K4 (0.43) | MAPKAPK2IKBKBKDRCDK4CCNA2 | |
| SCHEMBL2864567 | 0.75 | MAPKAPK2 (0.48) | MAPKAPK2IKBKBPIK3CDPIK3CAPIK3CB | |
| SCHEMBL2865030 | 0.75 | MAPT (0.41) | KDRADORA2AKDM4EALDH1A1MAPT | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL2861585 | 0.74 | NPC1 (0.40) | MAPKAPK2BTKKDRCDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1380576-A1 | NOVEL 1H-INDAZOLE COMPOUND | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPKAPK2 18/4885BTK 1826/4885IKBKB 584/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | MAPKAPK2 26/4885BTK 2213/4885IKBKB 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.